DNAPrint Genomics, Inc. (DNAG) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 1.53: the stock has moved about 53% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerDNAPrint Genomics, Inc. (DNAG) trades at $0.00002. DNAPrint Genomics, Inc. focuses on developing and marketing genetic testing products and services for ancestry, forensics, and pharmaceutical applications. Sector: Healthcare.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for DNAG: DNAG does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
DNAPrint Genomics, Inc. (DNAG) Healthcare & Pipeline Overview
DNAPrint Genomics, Inc. specializes in genetic testing products and services, offering ancestry analysis, forensic DNA tools, and genotyping systems. With a focus on serving forensic science, genealogical research, and pharmaceutical development clients, the company operates in the competitive biotechnology sector, marked by rapid innovation and evolving regulatory landscapes.
What Is the Investment Thesis for DNAG?
DNAPrint Genomics, Inc. operates in the niche market of genetic testing with products like AncestryByDNA and DNAWitness. The company's gross margin of 31.0% indicates potential for profitability if sales increase. However, the negative P/E ratio and a profit margin of -507.5% highlight significant financial challenges. Growth catalysts include expanding applications of RETINOME in forensics and increased adoption of GenomeLab SNPstream Genotyping System. Key risks involve the company's ability to achieve profitability and manage its operational costs. The high beta of 1.53 suggests the stock is more volatile than the market, adding a layer of risk for investors. Success hinges on effective commercialization and strategic partnerships.
Based on FMP financials and quantitative analysis
DNAG Key Highlights
Gross Margin of 31.0% indicates potential for profitability with increased sales volume.
- Profit Margin of -507.5% reflects significant operational losses and the need for improved cost management.
- Beta of 1.53 suggests higher volatility compared to the overall market, indicating a riskier investment.
- Market Cap of $0.00B indicates the company is a micro-cap stock with limited liquidity.
- The company serves diverse sectors including forensic science, genealogical research, consumer products, and pharmaceutical development, providing multiple revenue streams.
Who Are DNAG's Competitors?
DNAG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 77 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
| PLX Protalix BioTherapeutics, Inc. | $2.71 | +1.12% | $218M | 73 5-pillar |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | 68 5-pillar |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | 67 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DNAG's Key Strengths?
Specialized genetic testing products and services.
- Expertise in ancestry analysis and forensic DNA tools.
- Diverse customer base across multiple sectors.
- Proprietary technologies like RETINOME and GenomeLab SNPstream.
What Are DNAG's Weaknesses?
Negative profit margin and financial losses.
- Limited market capitalization and liquidity.
- Dependence on niche markets.
- Unknown disclosure status on the OTC market.
What Are the Key Risks for DNAG?
Financial-distress signal — its Altman Z-Score of -30.04 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Negative profit margin and financial losses impacting long-term sustainability.
- Intense competition in the biotechnology industry.
- Stringent regulatory requirements and compliance costs.
- Technological obsolescence of existing products.
- Limited market capitalization and liquidity on the OTC market.
What Are DNAG's Competitive Advantages?
- Proprietary genetic testing technologies and assays.
- Expertise in forensic DNA analysis and phenotyping.
- Established relationships with forensic science and research institutions.
- Diverse product portfolio catering to multiple market segments.
What Does DNAG Do?
DNAPrint Genomics, Inc., originally incorporated as Lexington Energy, Inc. in 1983, is a biotechnology company based in Sarasota, Florida, with a subsidiary in Leverkusen, Germany. The company develops and markets genetic testing products and services, catering to a diverse clientele across forensic science, genealogical research, consumer products, and pharmaceutical development. Its product portfolio includes AncestryByDNA, a pan-chromosomal assay for genetic ancestry; EurasianDNA, which measures European sub-ancestry; and EuropeanDNA, which reports a customer's proportional basic continental European ancestry. DNAPrint Genomics also offers DNAWitness, a tool used to determine genetic heritage from DNA samples obtained from crime scenes, and RETINOME, which provides a physical portrait of a person of interest based on a DNA sample. Additionally, RETINOME allows for inferring eye color from DNA. The company's GenomeLab SNPstream Genotyping System provides genotyping rates, utilizing a multiplexing format to generate data with minimal reagents. DNAPrint Genomics's focus on specialized genetic testing solutions positions it within a niche segment of the broader biotechnology market, emphasizing innovation and application across multiple sectors.
What Products and Services Does DNAG Offer?
- Develops and markets genetic testing products and services.
- Offers AncestryByDNA, a pan-chromosomal assay for genetic ancestry.
- Provides EurasianDNA, which measures European sub-ancestry.
- Offers EuropeanDNA, which reports proportional basic continental European ancestry.
- Provides DNAWitness to determine genetic heritage from crime scene DNA samples.
- Offers RETINOME, which provides a physical portrait based on DNA samples.
- Offers RETINOME, which allows inferring eye color from DNA.
- Provides GenomeLab SNPstream Genotyping System for genotyping.
How Does DNAG Make Money?
- Sales of genetic testing kits and services to consumers for ancestry analysis.
- Providing forensic DNA analysis tools and services to law enforcement agencies.
- Offering genotyping services and systems to pharmaceutical companies and research institutions.
- Generating revenue through strategic partnerships and collaborations in the healthcare sector.
What Industry Does DNAG Operate In?
DNAPrint Genomics, Inc. operates within the biotechnology industry, a sector characterized by rapid innovation, intense competition, and stringent regulatory oversight. The genetic testing market is experiencing growth, driven by advancements in technology and increasing demand for personalized medicine and ancestry services. DNAPrint Genomics competes with companies offering similar genetic testing services, including ancestry analysis and forensic DNA tools. The company's success depends on its ability to differentiate its products, navigate regulatory hurdles, and establish strategic partnerships within the evolving landscape.
Who Are DNAG's Key Customers?
- Individuals interested in ancestry and genealogy research.
- Law enforcement agencies and forensic laboratories.
- Pharmaceutical companies involved in drug discovery and clinical trials.
- Research institutions conducting genetic studies.
- Consumer product companies utilizing genetic data for product development.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
DNAPrint Genomics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Sarasota, US. The company is led by CEO Jatin Patel. DNAG has traded publicly since 2001.
Key Financial Metrics
Return on equity for DNAPrint Genomics, Inc. stands at 316.6%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.64 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
DNAPrint Genomics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -30.04 places it in the distress zone, a signal of elevated financial risk.
DNAG Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
DNAG Latest News
No recent news available for DNAG.
DNAG Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for DNAG.
Price Targets
Wall Street price target analysis for DNAG.
DNAG MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for DNAG; grades run from A+ (80-100) to F (below 30).
Leadership: Jatin Patel
CEO
Jatin Patel serves as the CEO of DNAPrint Genomics, Inc., managing a team of 24 employees. Information regarding Mr. His leadership is focused on guiding the company's strategic direction in the competitive biotechnology sector, emphasizing innovation and market expansion.
Track Record: Due to the limited information available, specific achievements, strategic decisions, and company milestones under Jatin Patel's leadership cannot be detailed. His tenure is marked by the ongoing development and marketing of genetic testing products and services, with a focus on serving forensic science, genealogical research, consumer products, and pharmaceutical development clients.
DNAG OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that DNAPrint Genomics, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may be subject to greater risks due to less stringent regulatory oversight. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies do not have to adhere to the same listing standards, potentially increasing the risk for investors.
- OTC Tier: OTC Other
- Limited Financial Disclosure: The unknown disclosure status increases the risk of investing in DNAG, as investors may lack access to crucial financial information.
- Low Liquidity: As an OTC Other stock, DNAG likely has low trading volume, making it difficult to buy or sell shares efficiently.
- Regulatory Scrutiny: OTC stocks are subject to less regulatory oversight, increasing the potential for fraud or mismanagement.
- Price Volatility: The combination of low liquidity and limited disclosure can lead to significant price swings.
- Going Concern Risk: Companies in the OTC Other tier may face a higher risk of financial distress or bankruptcy.
- Verify the company's financial statements and SEC filings, if available.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Determine the company's revenue sources and profitability.
- Investigate any legal or regulatory issues involving the company.
- Consult with a financial advisor to assess the risks and potential rewards.
- Check for any news or press releases about the company's performance.
- Longevity in the market since incorporation in 1983.
- Development of specialized genetic testing products.
- Serving diverse sectors including forensic science and pharmaceutical development.
- Subsidiary in Leverkusen, Germany, indicating international presence.
DNAG Healthcare Stock FAQ
What are the main risks for DNAG?
The main risks for DNAPrint Genomics, Inc. include its negative profit margin and ongoing financial losses, which raise concerns about its long-term sustainability.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial data available for DNAPrint Genomics, Inc.
- OTC market stocks are inherently more risky than exchange-listed stocks.